Coherus Oncology (CHRS) Operating Leases (2019 - 2026)

Coherus Oncology (CHRS) has 8 years of Operating Leases data on file, last reported at $954000.0 in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 66.57% year-over-year to $954000.0; the trailing twelve-month figure through Mar 2026 stood at $954000.0 (down 66.57% YoY), and the FY2025 full-year result was $1.5 million, down 55.66% from the prior year.
• Operating Leases declined to $954000.0 in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $6.8 million in Q2 2022 to a low of $954000.0 in Q1 2026.
• A 5-year average of $3.7 million and a median of $3.7 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases plunged 76.55% in 2023 and surged 160.24% in 2024, its largest moves.
• Tracing CHRS's Operating Leases over 5 years: stood at $5.0 million in 2022, then increased by 5.59% to $5.3 million in 2023, then plunged by 38.33% to $3.3 million in 2024, then slumped by 55.66% to $1.5 million in 2025, then slumped by 34.52% to $954000.0 in 2026.
• Business Quant data shows CHRS's Operating Leases at $954000.0 in Q1 2026, $1.5 million in Q4 2025, and $1.9 million in Q3 2025.